Overview

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Status:
Not yet recruiting

Trial end date:
2022-11-16

Target enrollment:

Participant gender:

Summary

Investigate the efficacy and safety of HSK16149 capsules in Chinese diabetic peripheral neuropathic pain (DPNP) following 13 weeks treatment in comparison to placebo.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Haisco Pharmaceutical Group Co., Ltd.

Treatments:

Pregabalin